Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating ...

THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, ...

The sample for the current study was restricted to the 40% of participants who were deemed to be successfully aging at the start of the study. Previous studies have shown that marriage is associated ...

The most effective ones tend to combine several emissions-cutting strategies, not a stand-alone approach, according to an examination of 1,500 policies globally. By Austyn Gaffney First, the good news ...